Lumos Pharma Inc. | NLNK - Operating Expenses

Newlink Genetics reported $9.35M in Operating Expenses for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Operating Expenses Change
Agenus AGEN:US USD 88.08M 23.66M
Bristol Myers Squibb BMY:US USD 9.46B 716M
Capricor Therapeutics CAPR:US USD 9.03M 956.93K
Celldex Therapeutics CLDX:US USD 29.5M 1.4M
Eli Lilly And LLY:US USD 5.47B 200.3M
Idera Pharmaceuticals IDRA:US USD 9.33M 3.96M
Intrexon XON:US USD 23.56M 776K
Merk MRK:US USD 10.32B 624M
Nektar Therapeutics NKTR:US USD 74.49M 3.43M
Newlink Genetics NLNK:US USD 9.35M 1.3M
Pfizer PFE:US USD 19.12B 5.9B
Prothena PRTA:US USD 50M 1.85M
Sarepta Therapeutics SRPT:US USD 367.84M 119.23M
Vascular Biogenics VBLT:US USD 3.4M 6.36M
YTE INCY:US USD 856.61M 171.68M